Manufacturing Issues Delay Half Of Pending BLAs, CBER’s Yetter Says
Executive Summary
Half of the active pending BLAs at the Office of Therapeutics Research & Review as of Jan. 1 have manufacturing concerns, Center for Biologics Evaluation & Research Associate Director-Review Management Robert Yetter, PhD, said
You may also be interested in...
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said
Biologics Approval Record Is “Excellent” Under PDUFA, FDA Says
The Center for Biologics Evaluation & Research's new product review performance has been "excellent" under the user fee program, FDA said
CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16
FDA's working group on CBER/CDER consolidation will meet for the first time the week of Sept. 16